Abstract
Background
Methods
Results
Conclusions
초록
배경
방법
결과
REFERENCES
















Fig. 1

Fig. 2

Table 1
Table 2
Patient No. | Drug resistance mutation | Following ART regimen | |||
---|---|---|---|---|---|
|
|||||
NRTI | NNRTI | PI | INSTI | ||
1 | None | 3TC, ABC | (-) | (-) | DTG |
3 | None | FTC, TAF | (-) | (-) | EVG/c |
5 | NNRTI(E138G)*, PI(A71T) | 3TC, ABC | (-) | (-) | DTG |
8 | NNRTI(E138G)*, PI(A71T) | FTC, TAF | (-) | (-) | EVG/c |
10 | None | FTC, TAF | (-) | (-) | EVG/c |
11 | None | 3TC, ABC | (-) | (-) | DTG |
12 | None | FTC, TAF | (-) | (-) | DTG |
15 | PI(L10I) | 3TC, ABC | (-) | (-) | DTG |
17 | None | FTC, TAF | (-) | (-) | DTG |
18 | PI(L10I) | 3TC, ABC | (-) | (-) | DTG |
19 | None | FTC, TAF | (-) | (-) | DTG |
21 | PI(L10I) | FTC, TAF | (-) | (-) | EVG/c |
22 | None | 3TC, ABC | (-) | (-) | DTG |
23 | PI(L10I, A71V) | 3TC, ABC | (-) | (-) | DTG |
24 | PI(L10V, A71V) | 3TC, ABC | (-) | (-) | DTG |
25 | PI(L10I) | 3TC, ABC | (-) | (-) | DTG |
26 | None | 3TC, ABC | (-) | (-) | DTG |
27 | None | FTC, TAF | (-) | (-) | EVG/c |
30 | PI(A71V) | FTC, TAF | (-) | (-) | EVG/c |
32 | NNRTI(Y181C)* | 3TC, ABC | (-) | (-) | DTG |
33 | NNRTI(E138G)*, PI(A71T) | 3TC, ABC | (-) | (-) | DTG |
34 | PI(L10I, A71T) | 3TC, ABC | (-) | (-) | DTG |
37 | PI(A71T) | 3TC, ABC | (-) | (-) | DTG |
39 | PI(L10V) | FTC, TAF | (-) | (-) | DTG |
43 | PI(L10I), INI(E157Q) | 3TC, ABC | (-) | (-) | DTG |
44 | None | 3TC, ABC, FTC, TAF | (-) | (-) | DTG, EVG/c |
46 | None | 3TC, ABC | (-) | (-) | DTG |
47 | PI(A71V) | 3TC, ABC | (-) | (-) | DTG |
48 | PI(M46L, A71T) | 3TC, ABC | (-) | (-) | DTG |
49 | None | 3TC, ABC | (-) | (-) | DTG |
50 | PI(L33F) | 3TC, ABC | (-) | (-) | DTG |
53 | None | 3TC, ABC | (-) | (-) | DTG |
55 | PI(A71V) | FTC, TAF | (-) | (-) | EVG/c |
56 | None | 3TC, ABC | (-) | (-) | DTG |
57 | None | 3TC, ABC | (-) | (-) | DTG |
61 | PI(L10I) | 3TC, ABC | (-) | (-) | DTG |
Abbreviations: ART, antiretroviral therapy; DRM, drug resistance mutation; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease inhibitor; INSTI, integrase strand transfer inhibitor; 3TC, lamivudine; ABC, abacavir; FTC, emtricitabine; TAF, tenofovir alafenamide; DTG, dolutegravir; EVG/c, elvitegravir/cobicistat.
Table 3
Abbreviations: ART, antiretroviral therapy; SGRT, standard genotypic resistance testing; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease inhibitor; INSTI, integrase strand transfer inhibitor; ZDV, zidovudine; 3TC, lamivudine; ABC, abacavir; FTC, emtricitabine; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate; EFV, efavirenz; LRV/r, lersivirine/ritonavir; ATV/c, atazanavir/cobicistat; DRV/c, darunavir/cobicistat; RAL, raltegravir; DTG, dolutegravir; EVG/c, elvitegravir/cobicistat.
Table 4
DRM type | Initial CD4 count/μL before ART* | Final CD4 ≥350/μL after ART† | |||
---|---|---|---|---|---|
|
|||||
<200 | 200–349 | 350–499 | ≥500 | ||
None (N = 14) | 2 | 9 | 2 | 1 | 12 (85.7%) |
Minor (N = 14) | 3 | 5 | 2 | 4 | 12 (80.0%) |
Major (N = 4) | 3 | 0 | 0 | 1 | 3 (75.0%) |